BridgeBio Oncology Therapeutics Inc. (BBOT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$719.96M

MomentumView details →

1D Return

+0.90%

YTD Return

−28.19%

RSI (14)

51.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$719.96M

RSI (14)

51.3

MomentumView details →

1D Return

+0.90%

YTD Return

−28.19%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−56.36%

ROA (TTM)

−48.34%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+99.93%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.71

EPS Surprise

−24.81%

Beats (12Q)

0/12

Next Q EPS Est

−$0.69

Avg Surprise (4Q)

−48.87%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.69x

Quick Ratio

4.69x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−182.11M

Op. CF (TTM)

−193.14M

Next earningsNov 11, 2026 →

Latest newsMore news →

BridgeBio Oncology Therapeutics reported financial results for the second quarter ended June 30, 2026, and provided a business update.24d ago

Similar companies

Gyre Therapeutics, Inc.GYRE Zevra Therapeutics, Inc.ZVRA Verastem, Inc.VSTM Assembly Biosciences, Inc.ASMB Oculis Holding AGOCS Shattuck Labs, Inc.STTK Find similar companies →

Latest newsMore news →

BridgeBio Oncology Therapeutics reported financial results for the second quarter ended June 30, 2026, and provided a business update.24d ago